Antibody nomenclature typically follows standardized guidelines (e.g., WHO’s INN system). Examples from current databases include:
None align with "PROLM20," further supporting its absence in existing registries.
Recent studies highlight critical issues in antibody reproducibility and validation:
YCharOS findings: 50–75% of commercial antibodies for human proteins perform adequately in specific applications, but ~12 publications per target included data from failed antibodies .
KO cell line superiority: Knockout controls are essential for validating antibody specificity in Western blots and immunofluorescence .
The CPRIT Therapeutic Monoclonal Antibody Core outlines key stages :
Lead identification: High-throughput screening of B-cell libraries.
Optimization: Humanization, affinity maturation.
Production: Scalable expression (e.g., CHO cells).
If PROLM20 exists, it would likely follow this pathway, but no evidence of its progression was found.
A representative example from nephrology research :
| Parameter | Result (n=65) |
|---|---|
| Immunologic remission | 94% at 36 mo |
| Partial remission rate | 92% |
| Cumulative cyclophosphamide dose | 11.1 g (ABG) vs. 18.9 g (standard) |
This demonstrates the importance of antibody-guided dosing but does not reference PROLM20.
Database searches: Consult ClinicalTrials.gov, WHO INN, or proprietary registries (e.g., Antibody Society’s therapeutic list ).
Vendor outreach: Contact antibody suppliers (e.g., Thermo Fisher, Abcam) for unpublished data.
Collaborative networks: Engage with institutions like UF Health’s neurogenetics team or Neurimmune for proprietary pipelines.
STRING: 39947.LOC_Os07g11910.1
LM20 is a rat monoclonal antibody (IgM isotype) that specifically recognizes and binds to methyl esterified homogalacturonan, which is an α-1,4-linked domain of pectic polysaccharides found in plant cell walls. Importantly, LM20 does not bind to un-esterified homogalacturonan, making it highly specific for the esterified form. The antibody was developed in the laboratory of Paul Knox at the University of Leeds and recognizes this epitope across several plant species .
LM20 binds to a higher density esterified homogalacturonan epitope compared to other similar antibodies such as JIM7. This distinction is critical for researchers interested in studying different degrees of pectin methylesterification in plant tissues. While both recognize methyl-esterified homogalacturonan, their different binding preferences enable researchers to distinguish between variations in the esterification patterns of pectins .
For short-term stability, LM20 antibody should be stored at 2-8°C. For long-term stability, storage below -10°C is recommended, with careful attention to avoiding freeze/thaw cycles which can compromise antibody function. The antibody remains stable for more than 4 years when stored at 4°C according to manufacturer specifications. The preparation is supplied as a liquid in serum-free cell culture supernatant containing 0.02% sodium azide as a preservative .
LM20 has been specifically tested and validated for immunofluorescence microscopy (at a 1:10 dilution) and ELISA (also at a 1:10 dilution). These techniques allow researchers to visualize the spatial distribution of methyl-esterified homogalacturonan in plant tissues and quantify its abundance, respectively. Highly esterified citrus pectin serves as an effective positive control for these applications .
When designing experiments for comprehensive characterization of plant cell walls, LM20 can be incorporated into multi-antibody labeling protocols. For immunofluorescence, researchers can employ sequential or simultaneous labeling approaches using antibodies with non-overlapping host species or isotypes to avoid cross-reactivity. This approach is similar to the rational antibody design methods described for other target epitopes, where multiple binding regions can be engineered to enhance specificity and affinity .
For quantitative analysis of methyl-esterified homogalacturonan content using LM20:
ELISA: Prepare serial dilutions of your sample alongside a standard curve using highly esterified citrus pectin
Maintain consistent incubation times and temperatures across all samples
Include appropriate controls (positive: highly esterified citrus pectin; negative: un-esterified pectin)
For comparative studies, maintain identical experimental conditions across all samples
This approach parallels established protocols for other antibodies in which careful standardization enhances reproducibility .
Sample preparation significantly impacts LM20 epitope detection due to the complex architecture of plant cell walls. Consider these methodological approaches for optimizing epitope accessibility:
Chemical pretreatments:
Sodium carbonate (pH 11.4) for removal of ester crosslinks
Dilute alkali for removal of hemicellulose
Pectate lyase for enzymatic removal of non-esterified homogalacturonan
Fixation protocols:
Aldehydes (particularly paraformaldehyde) may mask methylesterified epitopes
Alcohol-based fixatives often preserve methylesterification patterns better
These considerations draw on principles similar to those used in antibody-epitope interaction studies for other targets, where sample preparation directly impacts the conformational state of the target epitope .
When facing discrepancies between immunolabeling and biochemical data:
Consider epitope masking: Other cell wall components may block LM20 access to its target, giving artificially low signal despite high methylesterification
Evaluate extraction efficiency: Biochemical assays may not extract all pectin fractions equally
Perform sequential extractions with:
Water (soluble pectins)
CDTA (calcium-bound pectins)
Na2CO3 (covalently bound pectins)
Compare LM20 labeling with other methods:
Ruthenium red staining
FT-IR spectroscopy
Complementary antibodies with different specificities
This methodological approach resembles troubleshooting strategies used in other antibody-based research where multiple orthogonal techniques help resolve conflicting data .
Advanced structural analysis of pectins can be achieved through combined enzyme-antibody approaches:
| Enzyme Treatment | Target Structure | Expected Effect on LM20 Binding | Research Application |
|---|---|---|---|
| Pectin methylesterase | Methyl esters | Decreased LM20 binding | Confirms specificity for methylesterified epitopes |
| Endo-polygalacturonase | Non-esterified HG regions | Minimal direct effect on LM20 epitopes | Reveals masked epitopes by removing adjacent structures |
| Rhamnogalacturonanase | Rhamnogalacturonan I | Potential increase in LM20 accessibility | Distinguishes HG from RG-I regions |
| α-L-arabinofuranosidase | Arabinan side chains | May increase LM20 accessibility | Examines side chain influence on backbone recognition |
This approach mirrors strategies used in rational antibody design studies where accessibility of the target epitope is carefully mapped and manipulated .
When comparing immunological and chemical detection methods:
Advantages of LM20:
High specificity for methylesterified homogalacturonan
Enables in situ visualization
Compatible with multi-labeling approaches
No interference with tissue morphology when properly applied
Advantages of chemical methods:
Provide quantitative degree of methylesterification
Not affected by epitope masking
Enable bulk tissue analysis
Recommended complementary chemical approaches:
Ruthenium red staining (basic)
m-Hydroxydiphenyl assay (quantitative)
FT-IR spectroscopy (structural)
This comparative framework draws on principles used in antibody validation studies where multiple orthogonal methods help establish reliability .
Understanding the limitations of antibody-based approaches is crucial:
Temporal resolution constraints:
Fixed-time sampling provides snapshots rather than continuous monitoring
Rapid enzymatic modifications may occur during sample preparation
Spatial resolution limitations:
Antibody size (~150 kDa) may limit penetration in dense tissues
Resolution typically limited to light microscopy (~200 nm)
Methodological workarounds:
Time-course experiments with rapid fixation
Cryofixation to preserve transient states
Super-resolution microscopy techniques
Correlative light and electron microscopy
These limitations parallel challenges encountered in antibody-based research across various fields, where the physical properties of antibodies influence experimental design .
Future improvements could leverage rational design methods similar to those described for other antibody targets:
Structure-guided modifications:
Complementary peptide grafting on CDR loops to enhance specificity
Antibody engineering to improve affinity while maintaining specificity
Development of single-domain variants with enhanced tissue penetration
Multi-epitope recognition:
Design of two-loop antibody variants to simultaneously recognize adjacent epitopes
Enhancement of binding affinity through cooperative binding interactions
Such approaches would follow principles demonstrated in rational antibody design studies where antibody complementarity-determining regions (CDRs) are engineered to optimize target interaction .
Advanced computational tools can significantly improve LM20-based research:
AI-backed platforms combined with structural biology data could:
Predict epitope accessibility in complex plant tissues
Model conformational changes during pectin modifications
Optimize antibody design for improved recognition
Machine learning algorithms can:
Identify patterns in immunolabeling distribution
Correlate labeling patterns with developmental or environmental factors
Predict effects of genetic modifications on pectin structure
These approaches leverage computational methods similar to those used in antibody redesign projects where machine learning enhances predictive capabilities .